TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35089156

Group type: EXPERIMENTAL
Intervention: Computer-generated and individually tailored feedback letters (CO)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: In-person counseling by research staff trained in motivational interviewing (PE)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 961
Study: 35089449

Group type: EXPERIMENTAL
Intervention: Digital Pill System (DPS) for measuring PrEP adherence
Number of subjects: 15
Study: 35089599

Group type: EXPERIMENTAL
Intervention: Combined IPC and pharmacological prophylaxis
Number of subjects: 14931

Group type: COMPARATOR
Intervention: IPC
Number of subjects: 14931
Study: 35089671

Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Polivy) added to rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study: 35089806

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) on Holter
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: VT inducibility during electrophysiology study
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: NSVT and VT inducibility
Number of subjects: 115

Group type: COMPARATOR
Intervention: LGE on CMR
Number of subjects: 115

Group type: COMPARATOR
Intervention: NSVT characteristics
Number of subjects: 115
Study: 35089812

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine and cisplatin (GC) plus atezolizumab (A)
Number of subjects: 39
Study: 35090035

Group type: EXPERIMENTAL
Intervention: Intravenous contrast agent administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial contrast agent administration
Number of subjects: 0
Study: 35090169

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 127
Study: 35090175

Group type: EXPERIMENTAL
Intervention: Carrageenan gel
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 255
Study: 35090560

Group type: EXPERIMENTAL
Intervention: Technical assistance (TA) visits by PPP program staff
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sensitizing and educating facility staff about PrEP
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Establishing formal and informal feedback and accountability mechanisms
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Empowering facility staff to address implementation challenges
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ineffective recruitment and referral of sero-different couples
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stockouts of laboratory resources and testing supplies
Number of subjects: 39
Study: 35090577

Group type: EXPERIMENTAL
Intervention: Clinician Notification (CN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation (CN+NF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Activation Guide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 50
Study: 35091395

Group type: EXPERIMENTAL
Intervention: ScanNav AI device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no AI device)
Number of subjects: 30
Study: 35091441

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 308
Study: 35091443

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 1 (prior radiotherapy/ALKi-pretreated)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 2 (no radiotherapy/ALKi-pretreated)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 3 (prior radiotherapy/ALKi-naïve)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 4 (no radiotherapy/ALKi-naïve)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 5 (patients with leptomeningeal carcinomatosis)
Number of subjects: 156
Study: 35091442

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 45
Study: 35091448

Group type: EXPERIMENTAL
Intervention: eHsp90α
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Inhibition of eHsp90α
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Endothelial cell-conditioned medium and recombinant human Hsp90α
Number of subjects: 103
Study: 35091445

Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg plus cetuximab-radiotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus cetuximab-radiotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus cetuximab-radiotherapy
Number of subjects: 18
Study: 35091462

Group type: EXPERIMENTAL
Intervention: Psoriasis
Number of subjects: 589

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 589

Group type: COMPARATOR
Intervention: Biological disease-modifying drugs
Number of subjects: 589

Group type: COMPARATOR
Intervention: Disease activity (ASDAS-CRP)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Functional capacity (HAQ-AS)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 589
Study: 35091465

Group type: EXPERIMENTAL
Intervention: Optic nerve lesion length measured on MRI at the acute phase of ON
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Optic nerve DIR hypersignal lesion length
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Macular ganglion cell-inner plexiform layer (GCIPL) volume measured on OCT
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low-contrast monocular visual acuity (LCMVA)
Number of subjects: 51
Study: 35091711

Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once-daily for 12 weeks
Number of subjects: 30
Study: 35091747

Group type: EXPERIMENTAL
Intervention: Plasma DHPPA concentration in NAFLD patients
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Increasing tertiles of plasma DHPPA
Number of subjects: 1880
Study: 35092056

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35092110

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35092128

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cells (PBSC)
Number of subjects: 60
Study: 35092506

Group type: EXPERIMENTAL
Intervention: Balstilimab (AGEN2034)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balstilimab plus zalifrelimab (AGEN1884)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (not specified)
Number of subjects: 0
Study: 35092583

Group type: EXPERIMENTAL
Intervention: AMG 986 200 mg
Number of subjects: 6
Study: 35093104

Group type: EXPERIMENTAL
Intervention: Audit-and-feedback intervention including reports on antibiotic harms, stakeholder engagement, patient and provider education, identification of local champions, and blended facilitation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audit-and-feedback intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0
Study: 35093126

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the cochlea
Number of subjects: 22
Study: 35093147

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) for fetuses with LSDs
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fetal gene therapy trial
Number of subjects: 181

Group type: COMPARATOR
Intervention: Postnatal ERT
Number of subjects: 181

Group type: COMPARATOR
Intervention: Using clinicaltrials.gov as a main source of information
Number of subjects: 181
Study: 35093163

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) administered once daily for 12 weeks.
Number of subjects: 6
Study: 35093164

Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XRB)
Number of subjects: 16
Study: 35093281

Group type: EXPERIMENTAL
Intervention: Technical success (VARC-3 criteria)
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Technical failure (VARC-3 criteria)
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Technical failure
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Cardiac technical failure
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Vascular technical failure
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Technical failure (periprocedural period 0-30 days)
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Technical failure (30-360 days)
Number of subjects: 1624
Study: 35093737

Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor physiotherapy treatment (12 weekly sessions)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor physiotherapy treatment
Number of subjects: 31
Study: 35093981

Group type: EXPERIMENTAL
Intervention: Confidential, phone-based text message intervention promoting HIV testing
Number of subjects: 145
Study: 35093998

Group type: EXPERIMENTAL
Intervention: Targeted congenital CMV screening with saliva sample for CMV PCR testing
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Otorhinolaryngologist assessment
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Valganciclovir treatment
Number of subjects: 236
Study: 35094066

Group type: COMPARATOR
Intervention: TKI only
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: TKI with RT (25-40 Gy in 5 fractions)
Number of subjects: 133
Study: 35094747

Group type: EXPERIMENTAL
Intervention: Endovascular stent grafting
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Open surgical replacement
Number of subjects: 886

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 886

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 886
Study: 35094896

Group type: EXPERIMENTAL
Intervention: Stockholm3 test with MRI and PSA ≥2 ng/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: PSA alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 35095477

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study: 35095783

Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not mentioned)
Number of subjects: 0
Study: 35095867

Group type: EXPERIMENTAL
Intervention: Trastuzumab with neoadjuvant chemotherapy
Number of subjects: 36
Study: 35096167

Group type: EXPERIMENTAL
Intervention: Inferior turbinate reduction during rhinoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rhinoplasty without inferior turbinate reduction)
Number of subjects: 0
Study: 35096250

Group type: EXPERIMENTAL
Intervention: DFD-29 40mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: COMPARATOR
Intervention: DFD-29 20mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Doxycycline 40mg
Number of subjects: 205
Study: 35096584

Group type: EXPERIMENTAL
Intervention: Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT)
Number of subjects: 114
Study: 35096709

Group type: EXPERIMENTAL
Intervention: Complementary feeding with protein-rich foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35097222

Group type: EXPERIMENTAL
Intervention: Azithromycin and cefixime combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 0
Study: 35098120

Group type: EXPERIMENTAL
Intervention: Improvisational dance intervention (met twice weekly for 60 min for 8 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Improvisational dance intervention
Number of subjects: 10
Study: 35098170

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebos plus ADT
Number of subjects: 581
Study: 35098333

Group type: EXPERIMENTAL
Intervention: Bortezomib treatment (neurotoxic drug)
Number of subjects: 66
Study: 35098345

Group type: EXPERIMENTAL
Intervention: Cetuximab (administered every 3 weeks, maximum of six doses) plus autologous expanded NK cells (infused the day after cetuximab administration)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NK cells expanded from peripheral blood mononucleated cells
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NK cells with high ADCC potential
Number of subjects: 7
Study: 35098347

Group type: EXPERIMENTAL
Intervention: Early breast cancer survivors (EBCS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Inactive controls (CON)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EBCS
Number of subjects: 33
Study: 35098818

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preventive anticoagulation
Number of subjects: 0
Study: 35099278

Group type: EXPERIMENTAL
Intervention: Loop, an Open-Source Automated Insulin Delivery System
Number of subjects: 0
Study: 35099394

Group type: EXPERIMENTAL
Intervention: Machine learning-based prognostication models incorporating clinical events and time-to-event information
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Baseline models using admission variables only
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Conventional ICU prediction models (SOFA score)
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: Final models incorporating clinical events and time-to-event information
Number of subjects: 1432
Study: 35099638

Group type: EXPERIMENTAL
Intervention: Multisegment reconstruction (MSR)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Halfscan reconstruction (HSR)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: MSR
Number of subjects: 134

Group type: COMPARATOR
Intervention: HSR
Number of subjects: 134
Study: 35099678

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib or gefitinib
Number of subjects: 0
Study: 35099783

Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory (PCI) intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: Non-PCI treatment pathway (control)
Number of subjects: 191
Study: 35100081

Group type: EXPERIMENTAL
Intervention: Medications for opioid use disorder
Number of subjects: 0
Study: 35100097

Group type: EXPERIMENTAL
Intervention: High-intensity drinking intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 35100339

Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA, 9 × 10^6 cells, administered as a priming immunization plus 2 boosters at 12, 30, and 90 days after ASCT.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard lenalidomide maintenance therapy started at 3 months after ASCT for all patients.
Number of subjects: 20
Study: 35100411

Group type: EXPERIMENTAL
Intervention: Hyperferritinemia (≥500 ng/mL) in 46 patients (26%)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hyperferritinemia (≥250 ng/mL) in 90 patients (52%)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: CAP patients (n = 174)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Age- and sex-matched controls without infection, n = 50, median ferritin level 102.8 ng/mL (IQR 53.5-185.7)
Number of subjects: 174
Study: 35100444

Group type: EXPERIMENTAL
Intervention: Gantenerumab (1,200 mg every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose gantenerumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose aducanumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bapineuzumab
Number of subjects: 0
Study: 35100459

Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 0
Study: 35100692

Group type: EXPERIMENTAL
Intervention: No changes in the CCND/CDK pathway
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Aberrations of genes in CCND/CDK, FGFR/FGF, and PI3K/AKT pathways
Number of subjects: 390
Study: 35100697

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy plus anti-EGFR therapy (specifics not available)
Number of subjects: 0
Study: 35100750

Group type: EXPERIMENTAL
Intervention: Acute suicidality presentation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Emergency department length of stay (LOS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9 (PHQ-9) scores
Number of subjects: 41
Study: 35100923

Group type: EXPERIMENTAL
Intervention: Classification of canonical babbling status based on CBR ≥ 0.15 by Speech Language Therapists (SLTs)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Assessment of CBR and total number of syllables by SLTs
Number of subjects: 484
Study: 35101049

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/sqm
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/sqm
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25 mg/sqm)
Number of subjects: 74
Study: 35101117

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 97
Study: 35101175

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Multi-lipid lowering therapies (LLT)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Non-high-income countries
Number of subjects: 751
Study: 35101540

Group type: EXPERIMENTAL
Intervention: Simulated residual quantitative flow ratio (QFR)
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Simulated residual QFR-guided strategy
Number of subjects: 2146

Group type: COMPARATOR
Intervention: Angiography-guided strategy
Number of subjects: 2146
Study: 35101772

Group type: EXPERIMENTAL
Intervention: Mos1.Gag and Mos2.Gag virus-like particle (VLP) formation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-expression of Mos1.Gag and Mos2S.Env
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mos2S.Env-decorated VLPs
Number of subjects: 0
Study: 35101886

Group type: EXPERIMENTAL
Intervention: Ambulatory care from diagnosis
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Ambulatory care after hospitalization
Number of subjects: 764

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 764
Study: 35101941

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 2234

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 2234

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy vs. Chemotherapy
Number of subjects: 2234
Study: 35102064

Group type: EXPERIMENTAL
Intervention: TIMP-1 expression in thrombi
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TIMP-1 expression in leukocytes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MMP-2, MMP-9, TIMP-1, TIMP-2 and EMMPRIN expression
Number of subjects: 33
Study: 35102335

Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 superagonist)
Number of subjects: 0
Study: 35102497

Group type: EXPERIMENTAL
Intervention: Brolucizumab (6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0
Study: 35102780

Group type: EXPERIMENTAL
Intervention: Home-based kinaesthetic motor imagery training
Number of subjects: 0
Study: 35103026

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-operative follow-up at 12 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-operative follow-up at 4 days
Number of subjects: 60
Study: 35103064

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus Obinutuzumab
Number of subjects: 32
Study: 35103596

Group type: EXPERIMENTAL
Intervention: Single full-length VAR2CSA ectodomain variant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35103767

Group type: EXPERIMENTAL
Intervention: Familial DCM defined by DCM in at least 1 first-degree relative; expanded familial DCM defined by DCM or either left ventricular enlargement or left ventricular systolic dysfunction without known cause in at least 1 first-degree relative.
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Familial DCM among Black probands compared to White probands.
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Familial DCM among Hispanic probands compared to non-Hispanic probands.
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Expanded familial DCM.
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Cumulative risk of DCM in first-degree relatives.
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: DCM hazard in first-degree relatives of non-Hispanic Black probands compared to non-Hispanic White probands.
Number of subjects: 1220
Study: 35103828

Group type: EXPERIMENTAL
Intervention: 80-kV 1.2 gI/s IDR protocol
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: 80-kV 0.96 gI/s IDR protocol
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: 80-kV protocols
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Standard 100-kV protocol
Number of subjects: 1213
Study: 35104158

Group type: EXPERIMENTAL
Intervention: Adoptive cell transfer of enriched neoantigen-specific tumor-infiltrating lymphocytes (TIL) in combination with pembrolizumab (≤ 4 doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TILs recognizing at least one immunogenic somatic mutation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TILs isolated and grown in culture
Number of subjects: 42
Study: 35105153

Group type: EXPERIMENTAL
Intervention: Abre venous self-expanding stent system
Number of subjects: 200
Study: 35105182

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 162

Group type: COMPARATOR
Intervention: Noneptifibatide (Control)
Number of subjects: 162
Study: 35105339

Group type: EXPERIMENTAL
Intervention: Variability of body mass index (BMI)
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: Variability of waist circumference (WC)
Number of subjects: 4073